Pricing
  1. JP-listed companies
  2. Linical Co., Ltd.
  3. Financials
  4. Total cash & short-term investments

Linical Co., Ltd.【JP:2183】

Market cap
¥6.9B
P/E ratio
-3.7x
Linical helps pharmaceutical companies develop and launch new drugs by providing clinical trial services, post-market safety monitoring, and drug discovery support.
SummaryFinancialsDividendsHistoryOwnershipWorkforce
Period EndTotal cash & short-term investments (Million JPY)YoY (%)
Mar 31, 20257,040-5.70%
Mar 31, 20247,465+6.01%
Mar 31, 20237,042+17.65%
Mar 31, 20225,986+17.73%
Mar 31, 20215,084-2.43%
Mar 31, 20205,211+3.07%
Mar 31, 20195,056-2.27%
Mar 31, 20185,173+18.79%
Mar 31, 20174,355+49.61%
Mar 31, 20162,911+65.76%
Mar 31, 20151,756

Income Statement

RevenueRevenue growth (%)Cost of revenueGross profitGross margin (%)Research & developmentSelling, general & administrativeOperating margin (%)Operating expenses Operating income Income before tax Pretax margin (%)Provision for income taxesEffective tax rate (%)Net income Net income margin (%)Earnings per shareDiluted EPSDividend payout ratio (%)Dividend per shareEBITDAEBITDA margin (%)

Balance Sheet

Cash and cash equivalents Marketable securities, current Total cash & short-term investmentsAccounts receivable, netInventoriesTotal current assetsProperty, plant and equipment, netMarketable securities, non-current Total non-current assetsTotal assets Accounts payableShort-term debtLong-term debt, current Total current liabilitiesLong-term debt, non-current Total non-current liabilitiesTotal liabilities Common stock and paid-in capital Retained earningsStockholders' equityTotal debtNet debtD/E ratio (%)Working capital

Cash Flow

Depreciation & amortizationStock-based compensationCash from operations Capital expendituresCash from investing Payments for dividends Repurchases of common stockProceeds from issuance of term debt, netRepayments of term debtCash from financing Free cash flowFCF margin (%)